Eosinophilic pancreatitis: a review of the pathophysiology, diagnosis, and treatment

Yue Sun¹, Dan Pan², Kai Kang¹, Ming-Jun Sun¹, Yi-Ling Li¹, Li-Xuan Sang ² and Bing Chang ¹,*

¹Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, P. R. China; ²Department of Geriatrics, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, P. R. China

*Corresponding author. Department of Gastroenterology, The First Affiliated Hospital of China Medical University. No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning, P. R. China. Tel: +86-24-83282563; Fax: +86-24-83282563; Email: cb000216@163.com

Abstract

Eosinophilic pancreatitis (EP) is an extremely rare disease caused by purely eosinophilic infiltration of the pancreas. EP is prone to being misdiagnosed as pancreatic cancer, causing unnecessary economic and physical harm to the patient. We report three cases of EP that were cured by steroids without relapse from 2017 to now. The clinical data of the three patients, including clinical manifestations, serological manifestations, imaging (ultrasound, computed tomography, and MRI), pathological diagnosis and treatment, and telephone follow-up of all patients, were retrospectively analysed. In addition, a literature search was conducted on the Web of Science and PubMed databases using key terms related to EP, considering case reports with no restrictions on the date of publication or language. In conclusion, we analysed 19 cases and determined the diagnostic criteria for EP. The diagnostic algorithm for EP can be used to diagnose EP easily. We hope that our standards and algorithm can reduce the rate of misdiagnosis and contribute to clinical diagnosis and treatment. In addition, we expect to evaluate more EP cases to test our diagnostic criteria and design a systematic diagnostic flow chart.

Key words: eosinophilic pancreatitis; rare disease; diagnostic criteria; mechanism diagram; systematic diagnostic flowchart

Background

Eosinophilic pancreatitis (EP) is characterized by a purely eosinophilic systemic infiltrate [1]. It is associated with elevated immunoglobulin E (IgE) levels, hypereosinophilia, and eosinophilic infiltrates in other organs [2]. EP is a rare disorder, with only 16 case reports in 40 years. The incidence of an increased number of eosinophils is <1% in all pancreatic specimens, as described in the files from the John Hopkins Hospital [1]. EP was first described in 1978 by G. Barresi as acute eosinophilic insulitis [3].

In the pancreas of the newborn of a diabetic mother, an eosinophilic infiltrate surrounding the islets and perivascular and periductular connective tissue was identified [3]. Eosinophil accumulation occurs in human pancreatitis more than with normal pancreatic tissue [4]. Typical presenting symptoms of EP include abdominal or mid-back pain and obstructive jaundice that mimic the presentation of pancreatic cancer [1, 2, 5–11]. Distinguishing between EP and pancreatic cancer is crucial because the treatments and prognoses of the two diseases are
very different. Manohar et al. [12] showed that eosinophilia is related to the progression of pancreatitis, including fibrosis and malignancy in humans. Pancreatic ductal adenocarcinoma is one of the deadliest malignant tumors with a 5-year survival rate of <6% [13]. Surgery is the cornerstone for decreasing perioperative morbidity and mortality [14], but it is unnecessary for EP patients. In all of the previously reported cases, eosinophilic infiltration of the pancreas was frequently noted after autopsy or pancreatic resection in patients with a suspected pancreatic tumor [1–3, 5–10]. In general clinical work, pancreatic tissue is obtained by surgical resection or biopsy. The disadvantages of both approaches can be divided into several groups: (i) the patient’s physical condition is so poor that he or she cannot undergo pancreatic surgery or pancreatic needle biopsy; (ii) some medical institutions do not have the ability to perform pancreatic puncture; and (iii) the patient is not willing to accept any invasive examination. Therefore, there is an urgent need for clinical diagnostic criteria that not only protect patients from surgical trauma, but also improve patient health earlier.

**Case presentation**

The data for three patients with EP treated at the First Affiliated Hospital of China Medical University (Shenyang, China) between 2014 and 2019 were collected. All cases were confirmed by pathology. All three patients were male, with an average age of 52 years (range, 43–67 years). The average time from onset to diagnosis was 2 months (range, 1–3 months) in three patients, with abdominal pain as the first symptom. One of them had allergic rhinitis. The detailed laboratory studies are available in Supplementary Tables 1–3.

Computed tomography (CT) scan showed a diffusely enlarged pancreas without a pancreatic duct, and the outline of the pancreas was blurred with stripes and multiple nodules surrounding it (Figure 1A and B). Magnetic resonance cholangiopancreatography (MRCP) analysis showed dilatation of the extrahepatic bile duct above the pancreatic segment, a thickened common-bile-duct wall and a distended gallbladder, and occlusion of the bile duct with tapering within the pancreas. Pancreatography showed a diffusely enlarged pancreas without a pancreatic duct (Figure 1C–E).

Endoscopic ultrasound (EUS)-guided pancreatic biopsy confirmed eosinophilic infiltration (Figure 2A and B) in one patient. In the other two patients, eosinophils (EOS) infiltration was also evident in the pancreatic pathology obtained by surgery.

After 7 days of methylprednisolone treatment at a dose of 80 mg per day, the patients’ peripheral eosinophil counts, liver-function tests, and serum IgE levels returned to normal ranges. Then, we adjusted the dosage of prednisone to 40 mg orally, reduced the dosage by 5 mg per week, and discontinued the hormone treatment after approximately half a year. One month later, repeated CT scan from the same patient showed that the pancreas had shrunk and the previous stripes that had been visible around the pancreas could no longer be observed (Figure 1F). After the patients had been discharged from the hospital for 16 months, a telephone follow-up showed that the patients were in good condition.

**Clinical presentations**

Since EP is a rare disorder, only 16 cases have been published to date. These cases have varying clinical manifestations. Patients with EP may experience common non-specific symptoms such as fatigue, nausea, fever, vomiting, diarrhea, anorexia, and weight loss. The typical clinical presentation may include jaundice or different degrees of abdominal pain. In these 19 patients, 17 had clinical symptoms of jaundice and abdominal pain. In addition, patients with jaundice usually have pruritus, acholic stools, and skin and/or scleral icterus. We tried to classify the clinical presentations of EP by the organs affected as pancreatic or extrapancreatic. The pancreatic presentations involve features of acute pancreatitis and obstruction caused by pancreatic enlargement, and thus mimic pancreatic cancer. As such, the common symptoms are abdominal pain with/without posterior radiation that spontaneously disappears within a few hours, obstructive jaundice, recurrent acute pancreatitis without a definite etiology, fever, nausea, vomiting, and weight loss. The extrapancreatic presentations are commonly caused by peripheral eosinophilia, infiltration of eosinophils into other organs, and an obstructive pancreatic mass. Furthermore, gastroenteritis, biliary-tree stricture, or other autoimmune responses are also common in these patients.

**Histology**

Overall, the histopathological changes in EP can be summarized as the following triad: (i) the pancreas has inflammatory pathologic changes that may be pseudocysts, parenchymal necrosis, atrophy, or fibrosis; (ii) there is no sign of tumor cells; and (iii) idiopathic inflammation with eosinophilia can be found on macroscopic examination of the pancreas.

Macroscopically, most EP cases present as a diffusely enlarged tail or head of the pancreas [1, 2, 5, 8–10]. A cyst in the pancreas that causes pancreatic-duct and common-bile-duct obstruction can be noted at the time of surgery [1, 7–10]. In addition, there are no stones or other materials in the common bile duct [2, 5, 9]. The cyst often shows areas of fibrosis and necrosis [1, 7–10]. The enlarged lymph nodes and infiltration of the lamina propria of neighboring organs such as the gallbladder, duodenum, spleen, and ampulla of Vater may be present in some cases [1, 2, 5, 7–9]. Cases of autoimmune pancreatitis (AIP) often involve ‘sausage-shaped’ enlargement of the pancreas [15] and EP is accompanied by a ‘rock-hard’ pancreas [1].

Microscopically, EP usually reveals numerous eosinophilic infiltrates with few other inflammatory cells. The area of the cyst may be marked by diffuse periductal and septal eosinophilic infiltration with intra- and interlobular fibrosis, multiple acinar foci, arteritis and/or phlebitis, and atrophy of the pancreatic parenchyma [1, 2, 5, 8–10]. The pancreas can be infiltrated by eosinophils with no sign of any tumor cells. Apart from the above-mentioned features, EP may present with different variants.

**Serology**

An abnormal serum eosinophil count was reported in 11 of our summarized 16 cases (Table 1) [1, 2, 5–10, 16]. An increased plasma level of eosinophils has been suggested as a characteristic of EP. The efficacy of IgE in the diagnosis of EP is obviously important. This condition is similar to the high plasma level of IgG that is seen in AIP patients and is related to an autoimmune mechanism. Elevated liver-function enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, and alkaline phosphatase are helpful in diagnosing hepatitis or cholestatic hepatitis in the majority of patients, as only small proportions of patients have normal values. In addition, elevated levels of direct bilirubin
Figure 1. Comparison of pancreatic and ductal imaging before and after steroid treatment. (A) and (B) The computed tomography scans (CT) show a diffusely enlarged pancreas without a pancreatic duct, and the outline of the pancreas is blurred with stripes and multiple nodules around it. (C) Magnetic resonance cholangiopancreatography (MRCP) shows a normal intrahepatic bile duct, dilated extrahepatic bile duct above the pancreatic segment, distended gallbladder, and occluded bile duct with tapering within the pancreas. (D) MRCP shows the thickness of the common-bile-duct wall. (E) MRCP shows a diffusely enlarged pancreas without a pancreatic duct. (F) Abdominal CT scan at 1-month follow-up reveals the pancreas decreased in size and the previous stripes around the pancreas cannot be observed.

Figure 2. Pancreatic pathology. Significant purely eosinophilic infiltration in a biopsy specimen obtained from the pancreatic tissue (H&E stain).
| Author          | Year | Age (years) | Sex | Presentation                                                                 | Peripheral eosinophilia (10^9/L) | IgE (U/mL) | Pancreatic imaging                                                                 | Histology of the pancreas                                                                 |
|-----------------|------|-------------|-----|-------------------------------------------------------------------------------|----------------------------------|------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Barresi et al.  | 1978 | 0           | F   | Spontaneous tremors, cyanosis                                                  | NA                               | NA         | NA                                                                                 | Marked infiltration of EOS                                                                 |
| Bastid et al.   | 1990 | 21          | M   | Epigastric pain                                                               | 0.72                             | NA         | Enlarged tail of the pancreas                                                      | Area of necrosis with an abscess rich in EOS                                               |
| Barthet et al.  | 1998 | 18          | M   | Epigastric pain, jaundice, weight loss                                         | 0.623                            | 204        | Mass in the head of the pancreas                                                   | Lobular fibrosis and atrophy with infiltration by EOS                                     |
|                 |      | 64          | M   | Jaundice, weight loss                                                         | 0.38                             | Normal     | Enlargement of the pancreas mostly in the head                                     | Fibrous tissues only in the pancreatic biopsy before surgery                               |
| Waguet et al.   | 2000 | 21 months   | M   | Eczema, fever, acholic stools                                                  | 0.7–13                           | NA         | Enlarged pancreas                                                                  | NA                                                                                        |
|                 |      | 4           | F   | Abdominal pain, fever, acholic stools, jaundice                               | 2.5                              | NA         | Enlarged pancreas                                                                  | NA                                                                                        |
| Euscher et al.  | 2000 | 36          | M   | Abdominal pain, nausea, anorexia, weight loss, fatigue                        | 0.156                            | NA         | Enlarged pancreatic head with a mass                                               | Fibrotic pancreas with a diffuse inflammatory infiltrate of mainly EOS                    |
| Abraham et al.  | 2003 | 60          | M   | Abdominal pain, jaundice                                                      | 1.46                             | NA         | Diffusely enlarged pancreas and a 4 × 3.5 cm mass of the pancreatic head           | Infiltration of the pancreas mainly by EOS                                                 |
|                 |      | 36          | F   | Abdominal pain                                                                | 1.75                             | NA         | Cystic pancreatic mass of the pancreatic head                                     | Infiltration of the pancreas mainly by EOS                                                 |
|                 |      | 41          | M   | NA                                                                            | 1.18                             | NA         | Pancreatic pseudocyst of the pancreatic head                                      | Infiltration of the pancreas mainly by EOS                                                 |
| Cay et al.      | 2006 | 14          | M   | Abdominal pain, vomiting, jaundice                                            | NA                               | 1,767      | Larger-than-normal pancreatic head and a mass in the head of the pancreas         | Significant eosinophilic infiltration in the pancreatic mass                               |
| Kakodkar et al. | 2015 | 39          | M   | Epigastric pressure, pruritus, diarrhea, acholic stools, jaundice              | 0.9                              | 135        | Mass in the head of the pancreas and a diffusely enlarged pancreas, especially in the head | Significant eosinophilic infiltration on core biopsy samples of the enlarged pancreatic head |
| Tian et al.     | 2016 | 39          | M   | Jaundice                                                                      | 0.69                             | Elevated   | Diffusely enlarged pancreatic head                                                 | Diffuse inflammatory infiltration of the pancreas primarily by EOS and fibrous-connective-tissue hyperplasia with collagenation |
|                 |      | 46          | M   | Abdominal pain, jaundice                                                      | 0.62                             | NA         | Diffusely enlarged pancreas and a mass in the pancreatic head                      | Diffuse inflammatory infiltration of the pancreas primarily by EOS and fibrous-connective-tissue hyperplasia with collagenation |
|                 |      | 41          | F   | Abdominal pain, jaundice, fatigue, anorexia, nausea, vomiting                | 0.19                             | Normal     | NA                                                                                 | Diffuse inflammatory infiltration of the pancreas primarily by EOS and fibrous-connective-tissue hyperplasia with collagenation |
| Reppucci et al. | 2017 | 44          | M   | Epigastric pain, nausea, vomiting                                             | 0.6                              | NA         | Coarse calcification of the pancreatic head                                       | Extensive eosinophilic infiltration and fibrosis of the pancreas                           |
| Present patient 1 | 2018 | 46          | M   | Epigastric pain, fever, weight loss                                           | 0.82                             | 307.2      | Diffusely enlarged pancreas                                                        | Diffuse inflammatory infiltration of the pancreas primarily by EOS and lymphoed-tissue hyperplasia |
| Present patient 2 | 2018 | 67          | M   | Epigastric pain, nausea, vomiting, weight loss                               | 0.3                              | 432        | Enlarged pancreatic tail with calcification                                       | Area of necrosis with a fibrous capsule rich in EOS                                     |
| Present patient 3 | 2018 | 43          | M   | Epigastric pain increased after oily-food intake                              | 0.23                             | 297        | Mass in the body of the pancreas                                                   | Marked infiltration of EOS                                                                |

F, female; M, male; NA, details not available; IgE, immunoglobulin E; EOS, eosinophils.
and total bilirubin are usually reported in cases that are complicated by obstructive jaundice. An elevated sedimentation rate, C-reactive protein level, and triglyceride level have also been reported in EP patients [2, 7, 8, 16].

**Imaging and EUS-FNA**

On CT scans of EP patients, the pancreas is diffusely enlarged, especially in the head and tail, and it sometimes has a hypoechogenic or heterogeneous mass that usually shows dilatation of the main duct and the intra- and extrahepatic bile ducts. These features may lead to a misdiagnosis of a pancreatic tumor and AIP. Occasionally, EP may present with coarse calcification of the pancreas on CT scan [2].

MRI/MRCP has some advantages in evaluating the morphology and anatomical structure of the bile duct. MRCP is useful for providing high-resolution images of the biliary tree and pancreatic duct in multiple planes of sections, and a maximum signal-intensity projection can be helpful when overall 3D views are needed [17]. In 2018, the Japanese Clinical Diagnostic Criteria for AIP supplemented MRCP as a complement to endoscopic retrograde cholangiopancreatography (ERCP) to some extent [18]. Therefore, MRCP can achieve similar images to cholangiopancreatography and can obtain similar effects to ERCP or percutaneous transhepatic cholangiography (PTC).

ERCP is used to observe the normality of the bile ducts and the main duct. Using this technique, it is possible to identify a double-duct stricture that is located at the level of the pancreas in patients with EP. In addition, the common bile duct with/without the main duct is usually dilated up to the level of stenosis. Similar technologies include EUS and PTC. These technologies are three minimally invasive methods for pancreatic biopsy.

EUS-guided fine-needle aspiration (EUS-FNA) has been generally used to sample pancreatic tissues since 1992 [19]. EUS-FNA is superior to other methods such as ERCP in terms of tissue acquisition and safety [20]. Furthermore, EUS-FNA for tissue samples is fundamental to avoiding unnecessary surgeries [21]. Clinically, EUS-FNA is an essential procedure for patients with suspected pancreatic cancer and AIP [20, 22]. The combination of a histologic diagnosis of EP with the other findings specified in our criteria improved the diagnostic accuracy, but EUS may reveal false-negative results.

**Pathophysiology**

The mechanism of EP is variable but often includes an abundant eosinophilic infiltrate in the pancreas (Figure 3). In past years, elevated numbers of eosinophils have been associated with asthma, helminth infections, and acute anaphylaxis [23]. Recent studies suggest that eosinophils can damage tissues and cause disease by eosinophil cytotoxic and pro-inflammatory mediators [2, 23]. In addition, eosinophils are pleiotropic multifunctional leukocytes and play a role in the initiation and propagation of numerous inflammatory responses, including parasitic infections, bacterial and viral infections, tissue injury, tumor immunity, and allergic disease [24]. Many factors influence the mechanism of eosinophilic regulation that induces an increase in eosinophils [25]. IgE-mediated mechanisms are commonly known to facilitate the degranulation of mast cells and basophils, and to promote Th2 immunity; these mechanisms not only protect against parasitic worms and noxious substances, but also trigger allergic reactions [26]. Greater amounts of IgE are found in eosinophils with higher levels of serum IgE [27]. Therefore, IgE is an important serological indicator for patients with EP, similar to the association between IgG4 and AIP. Hence, in patients with EP, healthcare providers should note whether the patient has a concomitant parasitic infection, pancreatic allograft rejection, drug reaction to carbamazepine, chronic pancreatitis, myeloproliferative disease, tumor, or other eosinophil-elevating conditions. These known causes can help us to better treat EP.

Differentiation of progenitor cells into eosinophils is induced by IL-5, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are secreted by activated Th2 cells [28]. Eosinophilia is a phenomenon in which the number of eosinophils is increased, likely because many eosinophilic inflammatory diseases suppress the apoptosis of eosinophils [29].
many allergic disorders, overexpression of IL-5 is crucial for delayed eosinophil apoptosis [38]. In addition, animal experiments have demonstrated that IL-5-deficient mice show reduced pancreatic eosinophilia [4]. Eosinophils are non-dividing terminally differentiated cells that die rapidly and undergo spontaneously apoptotic death without survival factors [31]. In addition to these missing survival factors, apoptotic factors can induce eosinophil apoptosis. The latter may be useful for triggering the resolution of unwanted eosinophil inflammatory responses to compounds such as steroids [30]. The bone marrow contains a pool of eosinophils, and the gastrointestinal tract is a gathering place for eosinophils outside of the circulation [25]. Integrins belong to the cell-adhesion receptor superfamily and are transmembrane heterodimers that bind to extracellular matrix ligands, cell-surface ligands, and soluble ligands [32]. The integrin β7/MAdCAM-1 pathway is responsible for the migration of leukocytes into the pancreas [33–35]. β7 integrins can be expressed by eosinophils and can mediate the diverse functions of eosinophils, such as rolling, firm adhesion, and migration [36]. Eotaxin-3 is the predominant CCR3 ligand and is markedly induced by IL-4 and IL-13, which are secreted by Th2 cells, and its expression is dependent on the transcription factor STAT6. In addition, CCR3 can recognize the levels of CC chemokines, including MCP-2, MCP-3, MCP-4, RANTES, eotaxin-2, and eotaxin-3 [37, 38]. However, the interaction between eotaxin-3 and CCR3 is an important mechanism in eosinophil transepithelial migration [39]. The CCR3 agonists that are secreted by epithelial cells of the digestive tract, in addition to VLA-4 (CD 99d/CD 29), have a homing effect on eosinophils [40]. Isolated human pancreatic myofibroblasts show high levels of eotaxin-3 expression that is induced by IL-4 and IL-13 [41]. IgE can activate eosinophils through the FcεRI signaling pathways [26].

Predominant eosinophilic infiltration of the pancreas is the common pathological feature of patients who vary widely in their radiographic features and clinical manifestations. EP can also be diagnosed when eosinophils are the predominant inflammatory cell type in the pancreatic resection [9].

**Table 2. Criteria for EP**

| Criterion                          | Pathological feature                                      |
|-----------------------------------|------------------------------------------------------------|
| Pancreatic imaging                | Diffuse or segmental/focal enlargement                     |
| Ductal imaging                    | Stricture or upstream dilatation                           |
| Serology                          | IgE elevated and peripheral eosinophils elevated           |
| Other organ involvement           | 1. Histology of extrapancreatic organs mainly infiltrated with eosinophils |
|                                  | 2. Radiological evidence such as bile-duct stricture, enlarged lymph nodes, or retroperitoneal fibrosis |
| Histology of the pancreas (core biopsy/resection) | 1. Pseudocyst, parenchymal necrosis, atrophy, and fibrosis infiltrated by mainly eosinophils |
| Response to steroids              | 2. Eosinophilic phlebitis                                  |
|                                  | Rapid (<2 weeks) radiologically demonstrable resolution or marked improvement in manifestations |

EP, eosinophilic pancreatitis; IgE, immunoglobulin E.

**Treatment**

Overall, the key to the successful treatment of EP is steroids without a laparotomy. However, owing to the high rate of malignant tumors, it has been proposed that surgery should be considered for patients with EP. The preoperative diagnosis of EP is difficult to establish; thus, there have not been many reports on pure steroid treatment of patients with EP. It is generally accepted that EP patients have a favorable prognosis. In our statistical analysis of 19 patients, 12 were cured and 1 died; the
outcomes among the remaining patients were not clearly indicated. Patients with EP have a relatively better prognosis than those with tumors.

Food allergy is defined as an adverse immune response to food [48]. Food allergy is mostly associated with an increase in Th2 cytokines, IgE, and eosinophils in response to allergens [49]. The first elimination diet for treatment of EP was published in 1995 and involved exclusive feeding of an amino-acid-based formula for ≥6 weeks [50]. The elimination diets consisted of eliminating the six food groups most commonly associated with food allergy in a pediatric population in Chicago (cow’s milk protein, wheat, eggs, soy, peanut/tree nuts, and fish and seafood) for 6 weeks [51]. Today, elimination diets are effective treatments for eosinophilic gastrointestinal disorders and

Figure 4. This schematic drawing shows a flow to diagnose. CT, computed tomography; MRI, magnetic resonance imaging; MRCP, magnetic resonance cholangiopancreatography; EP, eosinophilic pancreatitis; CA19–9, cancer antigen 19–9; IgE, immunoglobulin E; IgG4, immunoglobulin G4; OOI, other organ involvement; EOS, eosinophils; EUS, endoscopic ultrasound.
irritable bowel syndrome [52–54]. Food elimination may be a potentially effective treatment for EP. Topical/systemic corticosteroids and food elimination have led to significant reductions in tissue eosinophil counts [55].

**Diseases commonly coexisting with hypereosinophilic disease**

Food allergies manifest in a variety of clinical conditions within the gastrointestinal tract, skin, and lungs [56]. Manohar et al. [48] showed that acute pancreatitis has been provoked after the consumption of mustard, milk, eggs, bananas, fish, and kiwi fruits. Food allergies can cause the recruitment of eosinophils and increased serum IgE [56].

Eosinophilic high type 2 airway inflammation is present in ~50% of adults with asthma [57]. Eosinophilic esophagitis and asthma are frequently found as comorbid conditions in children/adults, and these two conditions have similar Th2 response-driven pathophysiology [58].

Eosinophils contribute to chronic intestinal inflammation in inflammatory bowel disease (IBD) patients [59]. In general, eosinophils are increased in IBD. Filippone et al. [60] suggested that eosinophils play an important role in IBD pathogenesis, with clear indications of changes in cytokine, chemokine, and receptor mediator profiling. Seasonal relapses of IBD may increase eosinophil activity because of exposure to allergens [61].

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease characterized by intrahepatic or extrahepatic stricture or both with bile-duct fibrosis [62]. Eosinophilia and an increase in serum IgE have been reported to be associated with PSC [63–65]. The pathogenesis of PSC may be associated with hypereosinophilic syndrome or allergic reactions [63]. Horiuchi et al. [66] suggested that eosinophils and products released by eosinophils such as major basic protein may lead to inflammation and fibrotic changes in the bile ducts.

**Conclusions**

At this stage, there are no clear diagnostic criteria and each patient’s clinical manifestations are different. We seek to determine the diagnosis through biochemical tests and imaging studies to reduce unnecessary surgery. A diagnosis of EP is made based on the histopathological examination of pancreatic sections. The results of histopathological examinations often show that the pancreas is purely or predominantly infiltrated by eosinophils with no sign of any tumor cells. Pancreatic-imaging studies may support the diagnosis. Increased serum IgE levels, systemic hypereosinophilia, and eosinophil infiltrates in other organs of the gastrointestinal tract may also lead to a diagnosis. If diagnostic uncertainty occurs, glucocorticoid diagnostic treatment may be beneficial. Since a preoperative diagnosis of EP is difficult to establish, most patients undergo laparotomy, since malignancy cannot be excluded. However, it must be stressed that invasive diagnosis and treatment can impact the prognosis of the patient. It can thus be suggested that prompt gastrointestinal and pancreatic biopsies should be performed in an effort to avoid unnecessary surgical intervention [8]. Due to their similar clinical and imaging features, a fair number of EP patients are misdiagnosed with pancreatic tumor. As treatment options and the extent of a particular therapy may vary considerably, it is essential to differentiate EP from a pancreatic tumor [1, 2, 5–10] and from other disorders, such as AIP [42, 67–70], leukemia [71], inflammatory myofibroblastic tumors [72], chronic pancreatitis [73], and histiocytosis X [74]. There is no international diagnostic standard or flow chart for EP at this stage. A retrospective analysis of the clinical manifestations, histology, serology, imaging, other organ involvement, and responses to steroid therapy was conducted for 19 patients with EP (Table 1). The purpose of this review was to evaluate and validate the clinical criteria (Table 2) and algorithm (Figure 4) for EP. Secondary EP should also be considered on the differential diagnosis.

Corticosteroids are the therapeutic gold standard for EP treatment. The initial dose is 80 mg/day of prednisolone and the imaging results are reviewed after 2–4 weeks of treatment. Steroids can induce apoptosis of eosinophils, suppress the synthesis and effects of eosinophil-survival factors, and stimulate phagocytic cells to engulf eosinophils [31, 75]. The rate of apoptosis in eosinophils is increased when the glucocorticoid receptor combines with dexamethasone [75]. Glucocorticoids can alleviate the suffering of patients and the economic costs to patients compared to surgical treatment. In addition, long-term hormone therapy is more beneficial to the prognosis of patients and reduces the recurrence rate.

**Supplementary Data**

Supplementary data is available at Gastroenterology Report online.

**Authors’ contributions**

Y.S., L.X.S., and B.C. conceived of the study and participated in its design and coordination. Y.S., K.K., and D.P. performed the literature research, analysed the data, and wrote the manuscript. B.C., M.J.S., and Y.L.L. corrected the manuscript. All authors read and approved the final manuscript.

**Funding**

Support Program for Young and Middle-Aged Science and Technology Innovation Talents of Shenyang [No. RC170446].

**Conflicts of interest**

None declared.

**References**

1. Abraham SC, Leach S, Yeo CJ et al. Eosinophilic pancreatitis and increased eosinophils in the pancreas. Am J Surg Pathol 2003;27:334.
2. Reppucci J, Chang M, Hughes S et al. Eosinophilic pancreatitis: a rare cause of recurrent acute pancreatitis. Case Rep Gastroenterol 2017;11:120–6.
3. Barresi G, Inferrera C, Luca F. Eosinophilic pancreatitis in the newborn infant of a diabetic mother. Anat Histol 1978;380:341–8.
4. Manohar M, Verma AK, Venkateshaiah SU et al. Role of eosinophils in the initiation and progression of pancreatitis pathogenesis. Am J Physiol-Gastr L 2018;314:G211–22.
5. Bastid C, Sahel J, Choux R et al. Eosinophilic pancreatitis: report of a case. Pancreas 1990;5:104–7.
6. Kakodkar S, Omar H, Cabrera J et al. Eosinophilic pancreatitis diagnosed with endoscopic ultrasound. ACG Case Rep J 2015;2:239–41.
7. Cay A, Imamoglu M, Cobanoglu U. Eosinophilic pancreatitis mimicking pancreatic neoplasia. Can J Gastroenterol 2006;20:361–4.
8. Barthe M, Hastier P, Buckley MJ et al. Eosinophilic pancreatitis mimicking pancreatic neoplasia: EUS and ERCP findings—is nonsurgical diagnosis possible? Pancreas 1998;17:419–22.
9. Euscher E, Vasswani K, Frankel W. Eosinophilic pancreatitis: a rare entity that can mimic a pancreatic neoplasm. Ann Diagn Pathol 2000;4:379–85.
10. Tian L, Fu P, Dong X et al. Eosinophilic pancreatitis: three case reports and literature review. Mol Clin Oncol 2016;4:559–62.
11. Vincent A, Herman J, Schulick R et al. Pancreatic cancer. Lancet 2011;378:607–20.
12. Manohar M, Verma AK, Singh G et al. Eosinophilic pancreatitis: a rare or unexplored disease entity? PG 2020;15:34–8.
13. Campa D, Pastore M, Capurso G et al. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANCreatic Diseas eReseArch (PANDoRA) consortium investigation. Int J Cancer 2018;142:290–6.
14. Mohammed S, George VB, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol 2014;20:9354–60.
15. Sun G. Focal autoimmune pancreatitis: radiological characteristics help to distinguish from pancreatic cancer. World J Gastroenterol 2013;19:3634.
16. Waguet J, Benamara MA, Chardot C et al. Common bile duct stenosis with hypereosinophilia and pancreatitis in childhood: report of 2 cases. Pediatr Radiol 2000;30:383–5.
17. Reinbold C, Bredt PM, Guibaud L et al. MR cholangiopancreatography: potential clinical applications. Radiographics 1996;16:309–20.
18. Kawa S, Kamisawa T, Notohara K et al. Japanese diagnostic criteria for autoimmune pancreatitis, 2018: revision of Japanese diagnostic criteria for autoimmune pancreatitis, 2011. Pancreas 2020;49:e13–4.
19. Vilmann P, Jacobsen GK, Henriksen FW et al. Eosinophilic pancreatitis: three case reports and literature review. Mol Clin Oncol 2016;8:379–85.
20. Kitano M, Yoshida T, Itonaga M et al. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol 2019;54:19–32.
21. De Moura DTH, Rocha RSDP, Jukemura J et al. A rare non-oncological pancreatic mass: eosinophilic pancreatitis diagnosis through EUS-FNA. Endosc Int Open 2019;07:E151–4.
22. Chari ST, Takahashi N, Levy MJ et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009;7:1097–103.
23. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000;105:651–63.
24. Hogan SP, Rosenberg HF, Moqbel R et al. Eosinophils: biological functions and roles in health and disease. Clin Exp Allergy 2008;38:709–50.
25. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007;27:357–75.
26. Sanjua MA, Sagar D, Kolbeck R. Role of IgE in autoimmunity. J Allergy Clin Immunol 2016;137:1651–61.
27. Gleich GJ, Adolphson CR. The eosinophilic leukocytosis: structure and function. Adv Immunol 1986;39:177–253.
28. Sanderson CJ. Eosinophil differentiation factor (interleukin-5). Immunology 1990;49:231–56.
29. Simon HU, Blaser K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol Today 1995;16:53–5.
30. Simon H. Molecules involved in the regulation of eosinophil apoptosis. Chem Immunol Allergy 2006;91:49–58.
31. Druilhe A, Leutev S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 2003;8:481–95.
32. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007;8:215.
33. Xu B, Cook RE, Michie SA. α4β7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice. J Autoimmun 2010;35:124–9.
34. Komajosophiya S, Reddy S, Nitschke K et al. Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy. J Leukocyte Biol 2001;70:510–7.
35. Hanninen A, Salmi M, Simelli O et al. Mucosa-associated (beta 7-integrinhigh) lymphocytes accumulate early in the pancreas of NOD mice and show aberrant recirculation behavior. Diabetes 1996;45:1173–80.
36. Barthel SR, Johansson MW, McNamee DM et al. Roles of integrin activation in eosinophil function and the eosinophil inflammation of asthma. J Leukocyte Biol 2008;83:1–12.
37. Ogilvie P, Bard G, Clark–Lewis I et al. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001;97:1920–4.
38. Loetscher P, Moser B, Baggioolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 2000;74:127–80.
39. Yuan Q, Campanella GS, Copin DM et al. Membrane-bound eotaxin-3 mediates eosinophil transepithelial migration in IL-4-stimulated epithelial cells. Eur J Immunol 2006;36:2700–14.
40. Gauvreau GM, Becker AB, Boulet L et al. The effects of an anti-CD11a mAb, eflazuminab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003;112:331–8.
41. Fujimoto T, Imaeda H, Takahashi K et al. Eotaxin-3 (CCL26) expression in human pancreatic myofibroblasts. Pancreas 2016;45:420–4.
42. Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatologists. Pancreas 2011;40:352–8.
43. de Pretis N, Amadio A, Frulloni L. Updates in the field of autoimmune pancreatitis: a clinical guide. Expert Rev Gastroenterol Hepatol 2018;12:705–9.
44. Sugumar A, Chari ST. Autoimmune pancreatitis. J Gastroen Hepatol 2011;26:1368–73.
45. Walker MM, Potter M, Talley NJ. Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. Lancet Gastroenterol Hepatol 2018;3:271–80.
46. Uppal V, Kreiger P, Kutsch E. Eosinophilic gastroenteritis and colitis: a comprehensive review. Clin Rev Allergy Immunol 2016;50:175–88.
47. Straumann A, Katzka DA. Diagnosis and treatment of eosinophilic esophagitis. Gastroenterology 2018;154:346–59.
48. Manohar M, Verma AK, Upaharahali Venkateshiah S et al. Food-induced acute pancreatitis. Dig Dis Sci 2017;62:3287–97.
49. Azouz NP, Rothenberg ME. Mechanisms of gastrointestinal allergic disorders. J Clin Invest 2019;129:1419–30.
50. Kelly KJ, Lazenby AJ, Rowe PC et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995;109:1503–12.
51. Kagalwalla AF, Sentongo TA, Ritz S et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006;4:1097–102.
52. Kliewer KL, Cassin AM, Venter C. Dietary therapy for eosinophilic esophagitis: elimination and reintroduction. Clinic Rev Allerg Immunol 2018;55:70–87.
53. Lenhart A, Ferch C, Shaw M et al. Use of dietary management in irritable bowel syndrome: results of a survey of over 1500 United States gastroenterologists. J Neurogastroenterol Motil 2018;24:437–51.
54. Kamal A, Pimentel M. Influence of dietary restriction on irritable bowel syndrome. Am J Gastroenterol 2019;114:212–20.
55. Pesek RD, Reed CC, Muir AB et al. Increasing rates of diagnosis, substantial co-occurrence, and variable treatment patterns of eosinophilic gastritis, gastroenteritis, and colitis based on 10-year data across a multicenter consortium. Am J Gastroenterol 2019;114:984.
56. Renz H, Allen KJ, Sicherer SH et al. Food allergy. Nat Rev Dis Primers 2018;4:17098.
57. Papi A, Brightling C, Pedersen SRE et al. Asthma. Lancet 2018;391:783–800.
58. Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic esophagitis: an important comorbid condition of asthma? Clinic Rev Allerg Immunol 2018;55:56–64.
59. Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroen 2013;29:7–14.
60. Filippone RT, Sahakian L, Apostolopoulos V et al. Eosinophils in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1140–51.
61. Miner PB. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol 1997;92:15–48.
62. Dyson JK, Beuers U, Jones DEJ et al. Primary sclerosing cholangitis. Lancet 2018;391:2547–59.
63. Shimomura I, Takase Y, Matsumoto S et al. Primary sclerosing cholangitis associated with increased peripheral eosinophils and serum IgE. J Gastroenterol 1996;31:737–41.
64. Grauer L, Padilla VM, Bouza L et al. Eosinophilic sclerosing cholangitis associated with hypereosinophilic syndrome. Am J Gastroenterol 1993;88:1764–9.
65. Watanabe H, Ohira H, Kuroda M et al. Primary sclerosing cholangitis with marked eosinophilic infiltration in the liver. J Gastroenterol 1995;30:524–8.
66. Horiuchi K, Kakizaki S, Kosone T et al. Marked eosinophilia as the first manifestation of sclerosing cholangitis. Intern Med 2009;48:1377–82.
67. Kawaguchi K, Koike M, Tsuruta K et al. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol 1991;22:387–95.
68. Eugène C, Gury B, Bergue A et al. Icterus disclosing pancreatic involvement in idiopathic hypereosinophilic syndrome. Gastroenterol Clin Biol 1984;8:966–9.
69. Zhang K, Liu X, Yi L et al. A case report of autoimmune pancreatitis associated with a pancreatic pseudocyst. Medicine 2018;97:e439.
70. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic’s HISORt criteria. J Gastroenterol 2007;42:39–41.
71. Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015.
72. Walsh SV, Evangelista F, Khettry U. Inflammatory myofibroblastic tumor of the pancreaticobiliary region: morphologic and immunocytochemical study of three cases. Am J Surg Pathol 1998;22:412–8.
73. Tokoo M, Oguchi H, Kawa S et al. Eosinophilia associated with chronic pancreatitis associated with chronic pancreatitis: an analysis of 122 patients with definite chronic pancreatitis. Am J Gastroenterol 1992;87:455–60.
74. Heerde PV, Egeler RM. The cytology of Langerhans cell histiocytosis (histiocytosis X). Cytopathol Offic J Br Soc Clin Cytol 1991;2:149–58.
75. Meagher LC, Cousin JM, Seckl JR et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422–8.